Long-term remission durability and functional status of patients treated for diffuse histiocytic lymphoma with the CHOP regimen

James Olen Armitage, M. A.E. Fyfe, J. Lewis

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Thrity-eight (51%) of 75 patients treated with CHOP for diffuse histiocytic lymphoma achieved complete remission. Twenty-three of the complete responders are currently alive in complete remission 24-78 months (median, 38 months) after discontinuing therapy. Eleven patients died from recurrent lymphoma and four patients died in complete remission from other causes. Evaluation of the 23 patients alive in complete remission found them mostly well and without serious sequelae to therapy. Comparison with 20 patients who were in the same age range, were disease free after surgery, and had no other therapy for colon cancer revealed only an increased frequency of sexual dysfunction in the chemotherapy-treated lymphoma patients. Sixty-one percent of patients who achieved complete remission with the CHOP regimen are long-term disease-free survivors and are generally well except for an apparently high frequency of sexual dysfunction.

Original languageEnglish (US)
Pages (from-to)898-902
Number of pages5
JournalJournal of Clinical Oncology
Volume2
Issue number8
DOIs
StatePublished - Jan 1 1984

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Lymphoma
VAP-cyclo protocol
Colonic Neoplasms
Survivors
Therapeutics
Drug Therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Long-term remission durability and functional status of patients treated for diffuse histiocytic lymphoma with the CHOP regimen. / Armitage, James Olen; Fyfe, M. A.E.; Lewis, J.

In: Journal of Clinical Oncology, Vol. 2, No. 8, 01.01.1984, p. 898-902.

Research output: Contribution to journalArticle

@article{7a7bcce416f844379b8e01dac4068c84,
title = "Long-term remission durability and functional status of patients treated for diffuse histiocytic lymphoma with the CHOP regimen",
abstract = "Thrity-eight (51{\%}) of 75 patients treated with CHOP for diffuse histiocytic lymphoma achieved complete remission. Twenty-three of the complete responders are currently alive in complete remission 24-78 months (median, 38 months) after discontinuing therapy. Eleven patients died from recurrent lymphoma and four patients died in complete remission from other causes. Evaluation of the 23 patients alive in complete remission found them mostly well and without serious sequelae to therapy. Comparison with 20 patients who were in the same age range, were disease free after surgery, and had no other therapy for colon cancer revealed only an increased frequency of sexual dysfunction in the chemotherapy-treated lymphoma patients. Sixty-one percent of patients who achieved complete remission with the CHOP regimen are long-term disease-free survivors and are generally well except for an apparently high frequency of sexual dysfunction.",
author = "Armitage, {James Olen} and Fyfe, {M. A.E.} and J. Lewis",
year = "1984",
month = "1",
day = "1",
doi = "10.1200/JCO.1984.2.8.898",
language = "English (US)",
volume = "2",
pages = "898--902",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

TY - JOUR

T1 - Long-term remission durability and functional status of patients treated for diffuse histiocytic lymphoma with the CHOP regimen

AU - Armitage, James Olen

AU - Fyfe, M. A.E.

AU - Lewis, J.

PY - 1984/1/1

Y1 - 1984/1/1

N2 - Thrity-eight (51%) of 75 patients treated with CHOP for diffuse histiocytic lymphoma achieved complete remission. Twenty-three of the complete responders are currently alive in complete remission 24-78 months (median, 38 months) after discontinuing therapy. Eleven patients died from recurrent lymphoma and four patients died in complete remission from other causes. Evaluation of the 23 patients alive in complete remission found them mostly well and without serious sequelae to therapy. Comparison with 20 patients who were in the same age range, were disease free after surgery, and had no other therapy for colon cancer revealed only an increased frequency of sexual dysfunction in the chemotherapy-treated lymphoma patients. Sixty-one percent of patients who achieved complete remission with the CHOP regimen are long-term disease-free survivors and are generally well except for an apparently high frequency of sexual dysfunction.

AB - Thrity-eight (51%) of 75 patients treated with CHOP for diffuse histiocytic lymphoma achieved complete remission. Twenty-three of the complete responders are currently alive in complete remission 24-78 months (median, 38 months) after discontinuing therapy. Eleven patients died from recurrent lymphoma and four patients died in complete remission from other causes. Evaluation of the 23 patients alive in complete remission found them mostly well and without serious sequelae to therapy. Comparison with 20 patients who were in the same age range, were disease free after surgery, and had no other therapy for colon cancer revealed only an increased frequency of sexual dysfunction in the chemotherapy-treated lymphoma patients. Sixty-one percent of patients who achieved complete remission with the CHOP regimen are long-term disease-free survivors and are generally well except for an apparently high frequency of sexual dysfunction.

UR - http://www.scopus.com/inward/record.url?scp=0021616828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021616828&partnerID=8YFLogxK

U2 - 10.1200/JCO.1984.2.8.898

DO - 10.1200/JCO.1984.2.8.898

M3 - Article

VL - 2

SP - 898

EP - 902

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -